First Observation of MTH FR 678 C-A (Ala222Ala) single nucleotide polymorphism

Kaynakça (1)

1. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, Van den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995; 10: 111-113 2. Guba SC, Fink LM, Fonseca V: Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 1996; 106: 709-722 3. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Eng J Med 1991; 324: 1149-1155 4. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PW: Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715 5. Lyon E: Discovering rare variants by use of melting temperature shifts seen in melting curve analysis. Clin Chem 2005; 51: 1331-1332 6. Erali M, Schmidt B, Lyon E, Wittwer C: Evaluation of electronic microarrays for genotyping factor V, factor II and MTHFR. Clin Chem 2003; 49: 732-739 7. Schneider JA, Rees DC, Liu YT, Clegg JB: Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998; 62: 1258-1260 8. Bourouba R, Houcher B, Djabi F, Egin Y, Akar N: The Prevalence of Methylenetetrahydrofolate Reductase 677 C-T, Factor V 1691 G-A, and Prothrombin 20210 G-A Mutations in Healthy Populations in Sétif, Algeria. Clin Appl Thromb Hemost 2009; 15 (5): 529-534 9. Ozdag H, Egin Y, Akar N: Prothrombin gene 20209 C >T along with the first description of a homozygous polymorphism at the 3’ downstream region +4 C >T in the Turkish population. Lab Hematol 2006; 12 (3): 131-133 10. Mahadevan MS, Benson PV: Factor V Null Mutation Affecting the Roche Light Cycler Factor V Leiden Assay. Clin Chem 2005; 51: 1533-1535